Topical tacrolimus for the treatment of secondary lymphedema

Topical tacrolimus for the treatment of secondary lymphedema

Secondary lymphedema is a debilitating disease with no cure. Here the authors show that topical application of an FDA-approved anti-T cell drug tacrolimus potently prevents development and alleviates pathologic changes of established lymphedema in mice, suggesting a new treatment for human patients.

Bibliographic Details
Main Authors: Jason C. Gardenier, Raghu P. Kataru, Geoffrey E. Hespe, Ira L. Savetsky, Jeremy S. Torrisi, Gabriela D. García Nores, Dawit K. Jowhar, Matthew D. Nitti, Ryan C. Schofield, Dean C. Carlow, Babak J. Mehrara
Format: Article
Language:English
Published: Nature Publishing Group 2017-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms14345

Internet

https://doi.org/10.1038/ncomms14345

Similar Items